Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

被引:0
|
作者
Mansuri, Zeeshan [1 ]
Ashraf, Hadiah [2 ]
Taikadan, Thahsin [3 ]
Rajith, Gokul [4 ]
Ayesha, Ayesha [5 ]
Fatima, Urooj [6 ]
Erzinger, Gabriel [7 ]
机构
[1] GCS Med Coll & Res Ctr, Dept Cardiol, Opp DRM Off,Naroda Rd, Ahmadabad 380025, Gujarat, India
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Calicut Med Coll, Kozhikode, India
[4] All India Inst Med Sci, Gauhati, India
[5] Shifa Coll Med, Islamabad, Pakistan
[6] Jinnah Sindh Med Univ, Karachi, Pakistan
[7] Univ Joinville Reg UNIVILLE, Joinville, Brazil
关键词
dual anti-platelet therapy; percutaneous coronary intervention; ticagrelor; ASPIRIN;
D O I
10.1097/MCA.0000000000001417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI. Methods PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I-2 test. Results Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups. Conclusion In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 50 条
  • [1] Meta-analysis of duration of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
    Khan, Safi U.
    Bin Riaz, Irbaz
    Rahman, Hammad
    Lone, Ahmed N.
    Raza, Munis
    Khan, Muhammad Shahzeb
    Riaz, Anum
    Kaluski, Edo
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (04) : 429 - 432
  • [2] THE OPTIMAL DURATION OF DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
    Ma Yi-Tong
    Yu Zi-Xiang
    Yang Yi-Ning
    Bayinsilema, Ba
    HEART, 2013, 99 : A48 - A48
  • [3] Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Bavishi, Chirag
    Trivedi, Vrinda
    Singh, Mandeep
    Katz, Edward
    Messerli, Franz H.
    Bangalore, Sripal
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (11): : 1325.e1 - 1325.e12
  • [4] Dual Antiplatelet Therapy Duration After Percutaneous Coronary Interventions of Left Main Coronary Artery Disease: A Meta-Analysis
    Braghieri, Lorenzo
    Badwan, Osamah Z.
    Reed, Grant
    Menon, Venu
    Ziada, Khaled
    Kapadia, Samir R.
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 205 : 422 - 424
  • [5] Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
    Valgimigli, Marco
    Gragnano, Felice
    Branca, Mattia
    Franzone, Anna
    da Costa, Bruno R.
    Baber, Usman
    Kimura, Takeshi
    Jang, Yangsoo
    Hahn, Joo-Yong
    Zhao, Qiang
    Windecker, Stephan
    Gibson, Charles M.
    Watanabe, Hirotoshi
    Kim, Byeong-Keuk
    Song, Young Bin
    Zhu, Yunpeng
    Vranckx, Pascal
    Mehta, Shamir
    Ando, Kenji
    Hong, Sung Jin
    Gwon, Hyeon-Cheol
    Serruys, Patrick W.
    Dangas, George D.
    McFadden, Eugene P.
    Angiolillo, Dominick J.
    Heg, Dik
    Calabro, Paolo
    Juni, Peter
    Mehran, Roxana
    JAMA CARDIOLOGY, 2024, 9 (05) : 437 - 448
  • [6] Meta-analysis comparing the safety and efficacy of ticagrelor monotherapy after a short course of ticagrelor-based dual antiplatelet therapy versus standard therapy in complex percutaneous coronary interventions
    Condello, Francesco
    Sturla, Matteo
    Terzi, Riccardo
    Polimeni, Alberto
    Stefanini, Giulio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [7] Meta-analysis comparing the safety and efficacy of ticagrelor monotherapy after a short course of ticagrelor-based dual antiplatelet therapy versus standard therapy in complex percutaneous coronary interventions
    Condello, Francesco
    Sturla, Matteo
    Terzi, Riccardo
    Polimeni, Alberto
    Stefanini, Giulio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [8] Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
    Eisen, Alon
    Bhatt, Deepak L.
    HEART, 2017, 103 (11) : 871 - 884
  • [9] Meta-Analysis of One-Month Dual Antiplatelet Therapy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
    Mohamed, Mohamed M. G.
    Shaikh, Safia
    Osman, Mohammed
    Kheiri, Babikir
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 166 : 138 - +
  • [10] Meta-Analysis of Brief Dual-Antiplatelet Therapy Duration After Percutaneous Coronary Intervention
    Krittanawong, Chayakrit
    Virk, Hafeez Ul Hassan
    Isath, Ameesh
    Wang, Zhen
    Naidu, Srihari S.
    Mehran, Roxana
    Birnbaum, Yochai
    Levine, Glenn N.
    Jneid, Hani
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 174 : 182 - 184